NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer
27.6.2017 16:00 | Business Wire
NOVALIQ GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the appointment of Gabriela Burian, MD, MPH, as NOVALIQ’s Chief Medical Officer (CMO).
Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading NOVALIQ’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. Dr. Burian has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions, including Global Program Medical Director at Novartis Pharma and Ophthalmology Early Program Leader at F. Hoffmann-La Roche. She founded and directs GB Biomed Advisors GmbH and serves as CMO for Iconic Therapeutics, Inc. She is a faculty member of the European School for Advanced Studies in Ophthalmology.
“NOVALIQ has a very exciting and robust dry eye therapy pipeline and has the potential to address significant clinical needs in retina and glaucoma as well,” said Dr. Burian. “With multiple pre-clinical and clinical stage programs in development, the company is strongly positioned to be a global leader in dry eye disease. My top priorities are to advance these programs toward regulatory submissions and to identify, develop and manage new drug development opportunities in glaucoma and retina diseases by harnessing the power of NOVALIQ’s proprietary EyeSol® technology, which enhances the topical bioavailability, stability and safety of traditionally insoluble or unstable drugs.”
Sonja Krösser, PhD, vice president of preclinical and clinical development will continue to lead NOVALIQ’s dry eye developments and remains responsible for the preclinical and clinical team. Dr. Krösser is a translational science and clinical development expert with more than 15 years in the biopharmaceutic industry and in-depth experience in dry eye disease. She was and will be instrumental in the advancement of NOVALIQ’s rich and differentiated dry eye product pipeline, which includes the CE-approved NovaTears®; NovaTears® Omega-3 a new preservative-free, multi-dose eye drop formulation expecting CE mark in 2017; CyclASol®, currently in Phase 2 clinical trials in the U.S.; and, the recently announced, first-in-class ocular pain and anti-inflammatory cannabinoid DED drug development program.
Dr. Burian will join NOVALIQ’s executive management team, reporting to the company’s managing director and CEO Christian Roesky, PhD. “I’m delighted to welcome Gabriela to NOVALIQ ,” said Dr. Roesky. “With Gabriela’s extensive experience leading medical and clinical development teams combined with Sonja’s demonstrated track record of advancing our dry eye pipeline, we are strengthening our mission to transform active pharmaceutical ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.”
About NOVALIQ– NOVALIQ GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. NOVALIQ’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. NOVALIQ has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. NOVALIQ’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
PacSci EMC Competes on National Stage as NASA iTech Innovation Competition Finalist20.7.2017 21:45 | Pressemelding
PacSci EMC recently participated as a finalist in NASA’s second iTech Forum, competing to have their innovative idea selected as one of the top 10 in a yearlong initiative to find and foster innovative solutions with the potential to benefit NASA and the nation in the future. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720006386/en/ Douglas Terrier, Acting Chief Technologist, NASA presents Peter Current, Steve Nelson, and Bret Omsberg with a certificate recognizing “PacSci EMC as a top 10 finalist of NASA iTech’s Cycle 2 on July 13, 2017.” Photo Credit: NASA The teams competed against entrepreneurs presenting their proposed solutions to tough technology challenges to judges consisting of NASA’s chief technologists, space industry leaders and potential investors. Hosted by the National Institute of Aerosp
Insulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe20.7.2017 20:01 | Pressemelding
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced plans to assume, on July 1, 2018, the distribution, sales, marketing, training and support activities of Insulet’s Omnipod System across Europe following the expiration of the Company’s global distribution agreement with Ypsomed AG (Ypsomed) on June 30, 2018. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720006257/en/ Insulet develops, manufactures and distributes the Omnipod System, the market-leading tubeless insulin management system, currently used by over 110,000 people living with diabetes worldwide. Since 2010, the Company has had an exclusive contract with Ypsomed to distribute Insulet’s Omnipod System across Europe
Xilam: H1 2017 Revenue: +67%20.7.2017 16:00 | Pressemelding
Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2017 revenue of EUR 9.239 million, an increase of 67%. The revenue breakdown is as follows: In EUR 000 30.06.2017 (1) 30.06.2016 Change New productions(2) 4,571 4,036 +13.3% Catalogue 4,652
Natalia Vodianova Joins PicsArt as Head of Aspiration20.7.2017 13:00 | Pressemelding
PicsArt, the leading image editing app and creative social network, today announced the appointment of Natalia Vodianova, the supermodel and philanthropist, as Head of Aspiration. In this new role, Natalia will inspire and suggest opportunities to drive positive change through creativity. She has also joined the company’s advisory board. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005372/en/ Natalia Vodianova, the supermodel and philanthropist, joins PicsArt as Head of Aspiration. (Photo: Business Wire) “We are thrilled to welcome a talent and role model like Natalia into our family,” said PicsArt CEO Hovhannes Avoyan. “Natalia has been deeply involved in bringing creative inspiration to the world through fashion and social commitment. She’ll help connect the fashion world and the
Pacific Drilling Announces Early Consent Deadline Results20.7.2017 13:00 | Pressemelding
Pacific Drilling V Limited (the “Issuer”), a wholly owned subsidiary of Pacific Drilling S.A. (NYSE: PACD) (together with its subsidiaries, the “Company”) announced today the results, as of 5:00 p.m. Eastern Daylight Time on July 19 (the “Early Consent Deadline”) of its previously announced private consent solicitation in respect of its 7.25% Senior Secured Notes due December 1, 2017 (the “Notes”) pursuant to which the Issuer is soliciting the consent of the holders of Notes to an extension of the maturity date of the Notes to June 1, 2018 in order to give the Company more time to negotiate a refinancing transaction or undertake a holistic restructuring with all of its creditors (the “Solicitation”). At the Early Consent Deadline, the Issuer has received consents of holders of the Notes comprising less than 66 2/3% of the aggregate principal amount of the Notes (disregarding Notes held by the
CloudHealth Technologies Expands Business in Europe20.7.2017 13:00 | Pressemelding
CloudHealth Technologies, the leader in cloud service management, today announced that it is expanding its customer base, partner list and business operations in the European region. Helping to fuel the expansion is $46 million in Series D funding, which the company secured in June. The funding round will help CloudHealth Technologies scale international operations and double the size of its global workforce. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005189/en/ CloudHealth Technologies Expands Business in Europe (Photo: Business Wire) Cloud adoption in EMEA is growing steadily, with the market projected to reach €44.8 billion by the year 2020, according to Market Research & Statistics1. As enterprises turn to the cloud to build apps and manage operations, they improve
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom